Actively Recruiting
Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 Mutation
Led by The First Affiliated Hospital of Soochow University · Updated on 2026-03-30
35
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To evaluate the efficacy and safety of Genetic subtype-matched targeted therapy in the treatment of treatment-naive diffuse large B-cell lymphoma with TP53 mutation.
CONDITIONS
Official Title
Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 Mutation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 18 to 70 years
- Able to understand and sign informed consent
- Eastern Cooperative Oncology Group performance status between 0 and 3
- Life expectancy of at least 3 months
- Newly diagnosed, untreated CD20-positive diffuse large B-cell lymphoma confirmed by pathology
- Measurable disease with PET-CT showing tumor size at least 1.5 cm in short-axis diameter
- Adequate bone marrow, liver, coagulation, and kidney function without recent blood transfusion or medication correction
- Females of childbearing potential must agree to use effective contraception during treatment and for 5 weeks after last dose
- Sexually active males must agree to use effective contraception during treatment and for 3 months after last dose
- No difficulty swallowing oral tablets or capsules
- Good compliance and willingness to follow visit schedules, dosing, laboratory tests, and examinations
You will not qualify if you...
- Previous systemic anti-tumor therapy
- Central nervous system involvement
- Recent or ongoing use of systemic adrenal corticosteroids above specified doses
- Active other cancers requiring treatment
- Uncontrolled or severe heart disease or arrhythmias
- Uncontrolled infection or infection needing intravenous antibiotics
- Active hepatitis B or C infection or syphilis; HIV infection
- Significant gastrointestinal problems affecting drug absorption
- History of bleeding disorders or need for long-term oral anticoagulation
- Pregnancy or breastfeeding
- Allergy to study drugs or ingredients
- Active psychiatric disorders, alcohol or drug dependence, or substance abuse
- Life-threatening diseases or conditions affecting safety or study compliance
- Other investigator-determined conditions making participation unsuitable
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China, 215006
Actively Recruiting
Research Team
C
Changju Qu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here